Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Jeffrey Jerome Ludwig Sells 9,437 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) insider Jeffrey Jerome Ludwig sold 9,437 shares of Puma Biotechnology stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $29,726.55. Following the sale, the insider now directly owns 108,951 shares in the company, valued at $343,195.65. The trade was a 7.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Puma Biotechnology Price Performance

Shares of NASDAQ:PBYI traded down $0.17 during trading on Friday, reaching $2.95. The stock had a trading volume of 844,494 shares, compared to its average volume of 763,397. The stock has a market capitalization of $144.81 million, a PE ratio of 6.15 and a beta of 1.08. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. Puma Biotechnology, Inc. has a 52 week low of $2.22 and a 52 week high of $7.73. The business’s 50-day moving average price is $2.99 and its 200 day moving average price is $2.98.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The company had revenue of $80.50 million for the quarter, compared to analyst estimates of $71.32 million. During the same quarter in the previous year, the firm earned $0.12 earnings per share. As a group, equities analysts predict that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Hedge Funds Weigh In On Puma Biotechnology

Large investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in Puma Biotechnology in the 3rd quarter worth approximately $34,000. Franklin Resources Inc. acquired a new stake in shares of Puma Biotechnology in the 3rd quarter valued at $41,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Puma Biotechnology during the third quarter worth $44,000. Patriot Financial Group Insurance Agency LLC lifted its stake in shares of Puma Biotechnology by 72.7% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 8,000 shares during the period. Finally, Royce & Associates LP lifted its position in Puma Biotechnology by 71.8% during the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 8,427 shares during the period. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PBYI has been the topic of a number of analyst reports. StockNews.com cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Monday, December 23rd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.